Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 281 full-time employees. The company went IPO on 2013-12-03. The firm is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. The company uses protein engineering capabilities to enable its understanding of protein structures and interactions and to design technologies and XmAb drug candidates with improved properties. The company is advancing its XmAb drug candidates into clinical-stage development. The company is focused on the Fc domain, which is part of an antibody that interacts with various segments of the immune system and controls antibody structural architecture. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Vudalimab, XmAb104, XmAb564, XmAb819, XmAb808, Plamotamab, Obexelimab, Sotrovimab, XmAb306/RG6323, and others.